Cadrenal Therapeutics, Inc. (CVKD) stock
CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.72−0.16 (-8.51%)
Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%
Cadrenal Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cadrenal Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$11.65M. For fiscal 2025 it was -$13.46M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.46M | – |
| FY2024 | Dec 31, 2024 | -$10.96M | – |
| FY2023 | Dec 31, 2023 | -$7.63M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.07M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.20M | – |
See a number that looks wrong?